Oncoproteins, heterochromatin silencing and microRNAs: a new link for leukemogenesis

Epigenetics : Official Journal of the DNA Methylation Society
Clara NerviFrancesco Grignani

Abstract

The pathogenesis of acute myeloid leukemias involves complex molecular events triggered by diverse alterations of genomic DNA. A limited number of initiating lesions, such as chromosomal translocations generating fusion genes, are constantly identified in specific forms of leukemia and are critical to leukemogenesis. Leukemia fusion proteins derived from chromosomal translocations can mediate epigenetic silencing of gene expression. Epigenetic deregulation of the DNA methylation status and of the chromatin "histone code" at specific gene sites cooperate in the pathogenesis of leukemias. The neutralization of these crucial oncogenic events can revert the leukemia phenotype. Thus, their identification and the study of their molecular and biological consequences is essential for the development of novel and specific therapeutic strategies. In this context, we recently reported a link between the differentiation block of leukemia and the epigenetic silencing of the microRNA-223 gene by the AML1/ETO oncoprotein, the product of the t(8;21) the commonest AML-associated chromosomal translocation. This finding indicates microRNAs as additional epigenetic targets for leukemogenesis and for therapeutic intervention in leukemias.

Citations

Sep 8, 2012·Cellular Oncology (Dordrecht)·Sadegh BabashahMasoud Soleimani
Jul 2, 2009·Reproduction, Fertility, and Development·S E RacedoH Niemann
May 27, 2010·The American Journal of Clinical Hypnosis·Bart J Walsh
May 15, 2009·Pharmacogenetics and Genomics·Zachary W VeitchAmadeo M Parissenti
Sep 26, 2013·Epigenomics·Francesca PaganoClara Nervi
Apr 16, 2014·Mutation Research. Reviews in Mutation Research·David A EastmondBabasaheb Sonawane
Jun 15, 2014·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Shawn S Badal, Farhad R Danesh
Jun 16, 2010·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·S N SlavovE M Rego
May 11, 2012·Developmental Neuroscience·Margo S Landers, Regina M Sullivan
Dec 20, 2011·Carcinogenesis·Charles GiardinaDaniel W Rosenberg
Aug 22, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Maria MesuracaGiovanni Morrone
Apr 17, 2021·Life Sciences·Rahim IranzadMehdi Yousefi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Nature Reviews. Cancer
Jianjun ChenJanet D Rowley
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Cameron K TebbiCindy L Schwartz
© 2022 Meta ULC. All rights reserved